Safety, Tolerability, and Pharmacokinetics of a Novel Mitochondrial Modulator, TRC150094, in Overweight and Obese Subjects: A Randomized Phase-I Clinical Trial.

Joshi, Deepa; Jamadarkhana, Prashant; Kumbhare, Suchit; Singh, Amarinder; Kotecha, Jignesh; Bunger, Deepak; Shiwalkar, Ajay; Mohanan, Anookh; Dutt, Chaitanya

Joshi, Deepa; Jamadarkhana, Prashant; Kumbhare, Suchit; Singh, Amarinder; Kotecha, Jignesh; Bunger, Deepak; Shiwalkar, Ajay; Mohanan, Anookh; Dutt, Chaitanya.

Afiliación

Joshi D; Torrent Pharmaceuticals Ltd., Ahmedabad, India.
Jamadarkhana P; Torrent Pharmaceuticals Ltd., Ahmedabad, India.
Kumbhare S; Torrent Pharmaceuticals Ltd., Ahmedabad, India.
Singh A; Torrent Pharmaceuticals Ltd., Ahmedabad, India.
Kotecha J; Torrent Pharmaceuticals Ltd., Ahmedabad, India.
Bunger D; Torrent Pharmaceuticals Ltd., Ahmedabad, India.
Shiwalkar A; Torrent Pharmaceuticals Ltd., Ahmedabad, India.
Mohanan A; Torrent Pharmaceuticals Ltd., Ahmedabad, India.
Dutt C; Torrent Pharmaceuticals Ltd., Ahmedabad, India.

Front Pharmacol ; 12: 729424, 2021.

Article en En | MEDLINE | ID: mdl-34603045

Palabras clave

TRC150094; cardiometabolic based chronic disease; dyslipidemia; hypertension; insulin resistance; mitochondrial modulator; pharmacokinetics; type 2 diabetes mellitus

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Front Pharmacol Año: 2021 Tipo del documento: Article País de afiliación: India Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google